CytoMed Therapeutics Ltd banner
C

CytoMed Therapeutics Ltd
NASDAQ:GDTC

Watchlist Manager
CytoMed Therapeutics Ltd
NASDAQ:GDTC
Watchlist
Price: 0.9967 USD 6.6% Market Closed
Market Cap: $11.8m

Intrinsic Value

The intrinsic value for CytoMed Therapeutics Ltd (GDTC) under the Base Case is 0.2417 USD. Compared with the current market price of 0.9967 USD, the stock appears Overvalued by 76% .

Intrinsic value calculated using Multiples
$0.2417

Do our valuations actually work? See backtest results .

GDTC Intrinsic Value
$0.2417
Overvaluation 76%
Intrinsic Value
Price $0.9967
C
Monitor GDTC
Get notified when the price drops
Track Buy Zone
20% below Intrinsic Value $0.19
Get notified when the price drops into your buy zone
Current Price $1
Intrinsic Value $0.24
Margin of Safety 20% $0.19
Or choose another margin of safety
0% below Intrinsic Value
10% below Intrinsic Value
30% below Intrinsic Value
40% below Intrinsic Value
50% below Intrinsic Value
Custom
Ask AI Assistant
What other research platforms think about GDTC?

Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.

Discover External Valuations
Why is GDTC valued this way?

Let our AI break down the key assumptions behind the intrinsic value calculation for CytoMed Therapeutics Ltd.

Explain Valuation
Alternatives to GDTC

Fundamental Analysis

Financials
Efficiency

Earnings Waterfall
CytoMed Therapeutics Ltd

Wall St Price Targets

Capital Returns

Competitive Landscape

Ownership

GDTC Insider Trading
Buy and sell transactions by insiders

What is the Intrinsic Value of one GDTC stock?

The intrinsic value for CytoMed Therapeutics Ltd (GDTC) under the Base Case is 0.2417 USD.

Is GDTC stock undervalued or overvalued?

Compared with the current market price of 0.9967 USD, the stock appears Overvalued by 76% .

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett